Five Prime Therapeutics, Inc. (FPRX) Given Consensus Recommendation of “Buy” by Brokerages
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has received a consensus rating of “Buy” from the ten research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $65.20.
FPRX has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Cowen and Company initiated coverage on shares of Five Prime Therapeutics in a research note on Friday, March 24th. They issued an “outperform” rating on the stock. Jefferies Group LLC restated a “buy” rating and issued a $55.00 price objective on shares of Five Prime Therapeutics in a research note on Thursday, June 8th. ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Finally, TheStreet downgraded shares of Five Prime Therapeutics from a “c” rating to a “d+” rating in a research note on Monday, March 20th.
Shares of Five Prime Therapeutics (NASDAQ FPRX) traded up 1.50% on Monday, hitting $29.72. 178,474 shares of the stock traded hands. The stock has a 50-day moving average price of $29.94 and a 200 day moving average price of $39.01. Five Prime Therapeutics has a 12-month low of $26.65 and a 12-month high of $60.98. The stock’s market cap is $829.10 million.
Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.25. The company had revenue of $10.13 million during the quarter, compared to analyst estimates of $6.05 million. Five Prime Therapeutics had a negative return on equity of 21.81% and a negative net margin of 250.98%. The company’s revenue was up 55.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.49) EPS. On average, analysts anticipate that Five Prime Therapeutics will post ($4.67) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the company. FMR LLC increased its stake in Five Prime Therapeutics by 1.8% in the first quarter. FMR LLC now owns 4,343,501 shares of the biotechnology company’s stock worth $157,017,000 after buying an additional 77,381 shares in the last quarter. State Street Corp increased its stake in Five Prime Therapeutics by 25.7% in the first quarter. State Street Corp now owns 1,249,520 shares of the biotechnology company’s stock worth $45,175,000 after buying an additional 255,488 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Five Prime Therapeutics by 11.0% in the first quarter. Dimensional Fund Advisors LP now owns 933,410 shares of the biotechnology company’s stock worth $33,743,000 after buying an additional 92,338 shares in the last quarter. BB Biotech AG acquired a new stake in Five Prime Therapeutics during the first quarter worth $26,299,000. Finally, Victory Capital Management Inc. increased its stake in Five Prime Therapeutics by 8.8% in the first quarter. Victory Capital Management Inc. now owns 517,100 shares of the biotechnology company’s stock worth $18,693,000 after buying an additional 41,717 shares in the last quarter. Hedge funds and other institutional investors own 85.92% of the company’s stock.
WARNING: “Five Prime Therapeutics, Inc. (FPRX) Given Consensus Recommendation of “Buy” by Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/07/17/five-prime-therapeutics-inc-fprx-given-consensus-recommendation-of-buy-by-brokerages.html.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.